Design and optimization of novel paclitaxel-loaded folate-conjugated amphiphilic cyclodextrin nanoparticles

Erdoğar, Nazlı; Esendağlı, Güneş; Nielsen, Thorbjørn Terndrup; Şen, Murat; Öner, Levent; Bilensoy, Erem

doi:10.1016/j.ijpharm.2016.05.040

Cited by 50 publications

(31 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The smallest particle size was obtained without the surfactant for all nanoparticle formulations. This is found to be in accordance with previous studies reported in the literature proving that amphiphilic CDs are able to form nanoparticles without the presence of surfactants [ 21 – 22 24 , 32 – 34 ] due to their favorable self-alignment properties at air–water or oil–water interface [ 35 ]. The mean particle size of amphiphilic CD nanoparticles increased linearly with concentration of surfactant.…”

Section: Resultssupporting

confidence: 93%

Development of polycationic amphiphilic cyclodextrin nanoparticles for anticancer drug delivery

Varan¹,

Benito²,

Mellet³

et al. 2017

Beilstein J. Nanotechnol.

Self Cite

View full text Add to dashboard Cite

Background: Paclitaxel is a potent anticancer drug that is effective against a wide spectrum of cancers. To overcome its bioavailability problems arising from very poor aqueous solubility and tendency to recrystallize upon dilution, paclitaxel is commercially formulated with co-solvents such as Cremophor EL® that are known to cause serious side effects during chemotherapy. Amphiphilic cyclodextrins are favored oligosaccharides as drug delivery systems for anticancer drugs, having the ability to spontaneously form nanoparticles without surfactant or co-solvents. In the past few years, polycationic, amphiphilic cyclodextrins were introduced as effective agents for gene delivery in the form of nanoplexes. In this study, the potential of polycationic, amphiphilic cyclodextrin nanoparticles were evaluated in comparison to non-ionic amphiphilic cyclodextrins and core–shell type cyclodextrin nanoparticles for paclitaxel delivery to breast tumors. Pre-formulation studies were used as a basis for selecting the suitable organic solvent and surfactant concentration for the novel polycationic cyclodextrin nanoparticles. The nanoparticles were then extensively characterized with particle size distribution, polydispersity index, zeta potential, drug loading capacity, in vitro release profiles and cytotoxicity studies. Results: Paclitaxel-loaded cyclodextrin nanoparticles were obtained in the diameter range of 80−125 nm (depending on the nature of the cyclodextrin derivative) where the smallest diameter nanoparticles were obtained with polycationic (PC) βCDC6. A strong positive charge also helped to increase the loading capacity of the nanoparticles with paclitaxel up to 60%. Interestingly, cyclodextrin nanoparticles were able to stabilize paclitaxel in aqueous solution for 30 days. All blank cyclodextrin nanoparticles were demonstrated to be non-cytotoxic against L929 mouse fibroblast cell line. In addition, paclitaxel-loaded nanoparticles have a significant anticancer effect against MCF-7 human breast cancer cell line as compared with a paclitaxel solution in DMSO. Conclusion: According to the results of this study, both amphiphilic cyclodextrin derivatives provide suitable nanometer-sized drug delivery systems for safe and efficient intravenous paclitaxel delivery for chemotherapy. In the light of these studies, it can be said that amphiphilic cyclodextrin nanoparticles of different surface charge can be considered as a promising alternative for self-assembled nanometer-sized drug carrier systems for safe and efficient chemotherapy.

show abstract

Section: Resultssupporting

confidence: 93%

Development of polycationic amphiphilic cyclodextrin nanoparticles for anticancer drug delivery

Varan¹,

Benito²,

Mellet³

et al. 2017

Beilstein J. Nanotechnol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…shown that nanosystems loaded with placlitaxel enhance tumor cell sensitivity via folic acid targeting, increasing the cellular uptake of the drug. In this sense, cyclodextrin nanoparticles and liposomes decorated with folic acid and loaded with PTX significantly increased in vitro drug efficacy on ZR75-1 [6] and MCF-7 and MDA-MB-231 cells (FR-αpositive) respectively, decreasing IC50 values. In the case of liposomes the IC50 of folate decorated formulations were 2,2 and 11.5 times lower than nondecorated ones for MCF7 and MDA-MB-231 cells respectively.…”

Section: Introductionmentioning

confidence: 93%

“…Folic acid is one of the most promising ligands due to: (i) the overexpression of folate receptor-α (FR-α) in numerous kinds of tumors including ovarian, breast, kidneys, lung, uterus, and colon carcinomas; showing folic acid a high binding affinity for these receptors (Kd~10 10 M -1 ); (ii) its low immunogenicity, (iii) it is easy modify and (iv) its low cost [5,6]. This paper focuses on the use of folic acid decorated nanomedicines loaded with conventional anticancer drugs as targeted chemotherapy strategy in gynaecological cancers.…”

Section: Introductionmentioning

confidence: 99%

Targeted Chemotherapy via Folic Acid Decorated Nanomedicines

Torres-Suárez¹

2018

APCT

View full text Add to dashboard Cite

The development of nanomedicines decorated with ligands specifically recognized by cancer cells is a promising strategy to get a selective location of the antitumor drug at tumor cells, increasing its efficacy and reducing adverse effects. One of the most interesting ligands is folic acid, whose α-type-receptors are over expressed in numerous kinds of carcinomas. Several folic acid nanomedicines such as nanoparticles, micelles and liposomes have shown to increase the efficacy of conventional anticancer drugs in gynecological carcinomas, becoming in engaging therapeutics tools in these malignances.

show abstract

“…al. reported folic acid decorated amphiphilic β ‐CDs . Folic acid can complex with high affinity to the folate receptor, which is overexpressed on several cancer cells such as breast, ovary and lung .…”

Section: Amphiphilic Cds For Drug Deliverymentioning

confidence: 99%

Macrocyclic Amphiphiles for Drug Delivery

Zheng

Geng

et al. 2019

Israel Journal of Chemistry

View full text Add to dashboard Cite

Nanoparticles are the most crucial part of nanomedicine and various kinds of nanoparticles have been developed for drug delivery. As a new kind of nanoparticles, macrocyclic amphiphiles are gaining more and more attention in the field of nanomedicine due to their intrinsic features of molecular recognition and robust assembly. In this review, we summarized the reported works of drug delivery using macrocyclic amphiphiles, including cyclodextrin, calixarene, cucurbituril and pillararene species. These macrocyclic amphiphiles, serving as a new matrix of nanomedicine, can enhance drug solubility, improve drug stability, selectively deliver drugs to disease both in vitro and in vivo.

show abstract

Design and optimization of novel paclitaxel-loaded folate-conjugated amphiphilic cyclodextrin nanoparticles

Cited by 50 publications

References 59 publications

Development of polycationic amphiphilic cyclodextrin nanoparticles for anticancer drug delivery

Development of polycationic amphiphilic cyclodextrin nanoparticles for anticancer drug delivery

Targeted Chemotherapy via Folic Acid Decorated Nanomedicines

Macrocyclic Amphiphiles for Drug Delivery

Contact Info

Product

Resources

About